NBIX$132.555
Chart
Performance
Key Stats
AI NBIX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyNeurocrine Biosciences shows strong fundamental performance driven by its pharmaceutical pipeline and a healthy balance sheet. Thematic tailwinds in neurological disorders are significant. Technical indicators present a mixed short-term outlook, suggesting potential for consolidation after recent price action.
Thematic
Neurocrine Biosciences is well-positioned within the growing pharmaceutical sector, particularly in addressing unmet needs in neurological, neuroendocrine, and neuropsychiatric disorders. Advancements in treating conditions like tardive dyskinesia and endometriosis offer significant growth potential.
Fundamental
Neurocrine Biosciences demonstrates solid financial health with growing revenue and improving profitability. While the P/E ratio indicates a premium valuation, strong cash flow and a clean balance sheet support its growth trajectory.
Technical
The stock price has experienced a decline in the last month and is currently trading below key short-term moving averages. While long-term trends remain supportive, current momentum indicators suggest caution and potential for further short-term weakness.
| Factor | Score |
|---|---|
| Biotechnology & Pharmaceuticals Sector Growth | 90 |
| Neurological Disorder Market | 95 |
| Product Pipeline & R&D | 85 |
| Competitive Landscape | 80 |
| Regulatory Environment | 80 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 75 |
| Growth | 85 |
| Balance Sheet Health | 90 |
| Cash Flow | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 45 |
| Volume Confirmation | 60 |
| Support & Resistance | 70 |
| Short-Term Indicators | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Attractive Valuation Metrics
The stock's Price-to-Earnings (P/E) ratio (TTM) is 54.1, which, while higher than some sectors, is justified by strong revenue growth (1822.4M, +28.3% YoY) and expanding net margins (14.5% in 2024Q4 vs. 7.9% in 2021Q4). The Price/Sales (P/S) ratio of 7.1 is also supported by consistent revenue growth.
Strong Revenue and Profit Growth
Revenue has shown consistent growth, increasing from $1133.5M in 2021Q4 to $2355.3M in 2024Q4 (annualized). Net income has also grown significantly, with net margins expanding from 7.9% to 14.5% over the same period, indicating improving operational efficiency.
Bearish Points (7)
Significant EPS Misses in Recent Quarters
Recent EPS estimates have been significantly missed, with Q2 2025 estimate of $0.55 vs. reported $0.08 (-85.34% surprise) and Q1 2025 estimate of $1.56 vs. reported $1.0 (-35.92% surprise). This indicates a potential disconnect between market expectations and actual earnings delivery.
High P/E Ratio Relative to Earnings Growth
While revenue growth is strong, the trailing P/E ratio of 44.62 suggests a high valuation. The EPS for 2024Q4 was $1.24 against an estimate of $1.51, indicating a miss and potentially slowing earnings growth relative to valuation multiples.
Calendar
December 1995
29
Ex-Dividend Date
July 2025
31
Next Earnings Date
H: $1.80
A: $1.47
L: $0.94
H: 682.70M
A: 653.02M
L: 612.00M
Profile
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Seasonals
Price Target
163.11 USD
The 39 analysts offering 1 year price forecasts for NBIX have a max estimate of 192.00 and a min estimate of 115.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in tardive dyskinesia (Austedo vs. Ingrezza) and a major global pharmaceutical company focused on CNS disorders.
Weight: 95
Strategic partner for NBIX's endometriosis and uterine fibroid treatments (Orilissa/Oriahnn) and a significant player in neuroscience and women's health.
Weight: 92
Direct competitor and company focused on CNS, particularly Parkinson's disease psychosis (Nuplazid) and other neurological disorders.
Weight: 89
Strong neuroscience focus in sleep disorders and epilepsy, with an expanding pipeline in other neurological areas relevant to NBIX's broader CNS interests.